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The HIV-1 Vpr protein harbors a nuclear localization signal in its N-terminal domain. A peptide bearing this domain and
which is designated VprN has been used as a target to screen a phage display single chain Fv (scFv) library. Here we report
the isolation of anti-VprN scFv fragments from this library. The purified scFv fragments were able to bind the VprN peptide
in an ELISA-based system and to inhibit VprN-mediated nuclear import in permeabilized as well as in intact microinjected
cells. Furthermore, the anti-VprN scFv fragments recognized the full-length recombinant Vpr protein and inhibited its nuclear
import. The same scFv fragments did not inhibit nuclear import mediated by the nuclear localization signal of the SV40 large
T-antigen demonstrating a specific effect. The use of the described inhibitory anti-VprN scFv fragments to study nuclearKey Words: HIV-1; Vpr; nuclear import; phage display.
INTRODUCTION
During the last few years it has become clear that the
human immunodeficiency virus type-1 (HIV-1) is able to
infect terminally differentiated nondividing cells such as
macrophages and quiescent T-lymphocytes. This implies
that the HIV-1 genome is able to cross the intact nuclear
envelope via the nuclear pore complexes (NPC) of host
cells (Simm et al., 1993; Lewis et al., 1992). Following cell
penetration, the HIV-1 particles are uncoated and the
viral genome is converted to the preintegration complex
(PIC). The PIC is then imported into the nuclei of infected
cells by one or more of the viral karyophilic proteins
(Bukrinsky et al., 1992).
The ability of HIV-1 to infect nondividing cells distin-
guishes it from other retroviruses, such as the murine
leukemia virus (MLV), that infect only proliferating cells.
Indeed, PICs derived from many oncoretroviruses includ-
ing MLV are nonkaryophilic and therefore enter the nu-
cleus only during mitosis following the breakdown of the
nuclear envelope (Lewis and Emerman, 1994).
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Silberman Institute of Life Sciences, The Hebrew University of Jerusa-In the case of HIV-1, at least three viral proteins have
been proposed to be involved in nuclear import of the
PIC, including the matrix (MA) protein, the viral protein of
regulation (Vpr), and the viral integrase (IN) protein
(Bouyac-Bertoia et al., 2001; Jenkins et al., 1998; Depi-
enne et al., 2000; Bukrinsky et al., 1993). Thus, the nu-
clear import mechanisms may be partially redundant.
However, the respective contribution of each of these
karyophilic proteins to the nuclear import process of the
viral PIC is as yet not fully understood.
The current view of the involvement of the HIV-1
karyophilic proteins in nuclear import of the PIC is
based mainly on the inability of virus particles that are
deleted or mutated in one of these proteins to repli-
cate in nondividing cells (Haffar et al., 2000; Koostra
and Schuitemaker, 1999). However, due to the inherent
limitations of these studies, the involvement of the MA
and Vpr proteins for promoting nuclear import of the
PIC is still controversial. Also, conflicting data have
been reported on the function of the HIV-1 IN protein in
mediating nuclear import of the viral PIC (Bouyac-
Bertoia et al., 2001; Haffar et al., 2000; Petit et al.,
2000). Thus, the accurate role of the nuclear localiza-
tion signals (NLS) elucidated within the HIV-1 MA, Vpr,
and IN proteins and the function of each of these
sequences in virus infection continue to be a matter of
debate.
It appears that the role of Vpr in mediating nuclear
import of the HIV-1 PIC is indirect and requires theimport of viral karyophilic proteins and their therapeutic po
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has been shown that in certain cell lines, such as
growth-arrested T-cells, Vpr is required neither for nu-
clear import of the PIC nor for virus replication (Heinz-
inger et al., 1994; Gallay et al., 1997; Bukrinsky et al.,
1993). In such cells its role in promoting nuclear import of
the viral PIC was suggested to be substituted by cellular
proteins such as the Hsp70 (Agostini et al., 2000). Re-
cently, it has been reported that the Vpr protein induces
transient and localized herniations in the nuclear enve-
lope, and this process—as was suggested—provides a
portal for PIC entry into the nucleus (de Noronha et al.,
2001).
Vpr is a small protein that is composed of 96 amino
acids with a molecular weight of approximately 11 kDa
(Yuan et al., 1990; Baldrich-Rubio et al., 2001). Several
studies have shown that nuclear accumulation of this
protein may be promoted by both the N- and the C-
terminal domains (Jenkins et al., 1998). In our previous
study we used peptides derived from the Vpr to better
characterize its NLS region (Karni et al., 1998). We syn-
thesized peptides corresponding to the N- (residues 17
to 34) and C-terminal (residues 77 to 96) regions and
designated them as VprN and VprC, respectively. Indeed,
peptides derived from the N-terminal region of Vpr, but
not from its C terminus, promoted the entry of covalently
attached, labeled BSA molecules into nuclei of perme-
abilized HeLa cells (Karni et al., 1998). Our results—
which were consistent with previously published obser-
vations (Jenkins et al., 1998)—indicated that the Vpr
protein harbors a nonconventional, negatively charged
NLS in its N terminus (Karni et al., 1998; Jenkins et al.,
1998). Nuclear import of the BSA–VprN conjugates was
found to be energy and temperature dependent and was
inhibited by wheat germ agglutinin (WGA), demonstrating
that the observed import is an active process and occurs
via the NPC.
Antibodies and peptides that specifically mask the
NLSs of the HIV-1 karyophilic proteins and thus inhibit
their function may offer an alternative and novel ap-
proach to elucidating the exact role of the Vpr protein as
well as its relative contribution to the nuclear import
process of the HIV-1 PIC. Furthermore, such studies may
help in gaining a better understanding of the spatial
rearrangement of the karyophilic proteins within the PIC
complexes and their relative susceptibility to external
ligands. This approach may also be useful for obtaining
anti-viral drugs.
Here we have applied the phage display technology
and used a single chain Fv (scFv) phage display library
for isolation of scFv fragments against the VprN se-
quence. The library used in the present work is of a
diversity 108 and was built by the use of a repertoire of
in vitro rearranged human VH gene segments with ran-
dom nucleotide sequences encoding the CDR3 domain
(length of 4–12 residues) (Nissim et al., 1994). Using this
library we have been able to select more than 40 phages
bearing specific anti-VprN scFvs. The present results
show that the anti-VprN scFvs recognized the VprN pep-
tide. They did not, however, recognize peptides bearing a
mutated VprN or other NLSs, such as that of the SV40
large T-antigen (SV40 NLS). The anti-VprN scFv frag-
ments strongly inhibited import mediated by the VprN
peptide but not by the SV40 NLS. Furthermore, the anti-
VprN scFvs were able to specifically bind to and inhibit
nuclear import of a recombinant full-length Vpr–GST fu-
sion protein.
RESULTS
Selection of phage particles that possess specific
binding to the VprN peptide
The BSA–VprN nuclear conjugates (see Materials
and Methods; Karni et al., 1998) was used by us as a
target for selecting anti-VprN phage particles from a
semisynthetic phage display scFv library (Harrison et
al., 1996; Nissim et al., 1994). The BSA–VprN conjugate
was employed because attempts to use the free VprN
peptide as a target for the library were unsuccessful
(data not shown). To assure the selection of VprN-
binders and to exclude BSA-binders, phages selected
by the first-round panning were incubated with immu-
noblots coated with BSA molecules, and then unbound
particles were collected (see Materials and Methods).
This strategy significantly increased the percentage of
specific VprN-binders, which were around 7% of the
total particles screened, compared with the only about
0.5% obtained when the BSA panning step was omit-
ted. This double selection assured the isolation of
phage particles which possessed selective and spe-
cific affinity for the VprN sequence as demonstrated by
ELISA tests. Only those VprN-binders which exhibited
high and selective binding for BSA–VprN and not to the
other NLS–BSA conjugates were considered specific
binders for further analysis. BSA conjugates carrying
peptides with unrelated sequences were used to de-
tect unspecific binders (see Materials and Methods
and Fig. 1).
The results in Fig. 1A show that several colonies (1–4,
11) indeed possessed specific binding to VprN, while
other colonies also were able to bind other NLS–BSA
conjugates in addition to VprN (colonies 6–9) or did not
bind to any of the target molecules used (colonies 5, 10,
12). In our experiments over 40 specific binders, namely
phages which bind to VprN exclusively and not to other
NLSs, were selected (not shown). Quantitative estima-
tion of the binding abilities of three phage colonies (des-
ignated as phages A, B, C), which were chosen for their
strong and specific binding to the target sequence, are
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shown in Fig. 1B. These three colonies showed binding
abilities to the VprN about 10-fold higher than those to its
mutant (which differs from the wild-type peptide only by
three amino acids; see Materials and Methods) or to an
unrelated NLS, such as the SV40 NLS.
Anti-VprN scFv fragments possess high and specific
binding abilities to the VprN peptide
Highly purified scFvs with the appropriate molecular
weight (MW of 30 kDa) were obtained from phages A, B,
FIG. 1. Binding of selected phage colonies to the BSA–VprN conjugate. (A) Binding was estimated by the ELISA assay system (see Materials and Methods).
Numbers indicate individual phage colonies. The OD values were determined by an ELISA reader and converted to a gray scale. Note that black and white fields
indicate strong and no binding, respectively; gray fields indicate binding of intermediate strength. Also note that phages 1–4 as well as 11 exhibited strong and
specific binding to the VprN sequence. (B) Specific binding of the three selected phage colonies used in the present work to the BSA–VprN conjugate ( , phage
A;, phage B; , phage C). As can be seen, all three phage preparations specifically bound the BSA–VprN conjugate, but did not react with the BSA–VprNmutant
or the BSA–SV40 NLS. All experimental conditions were as described under Materials and Methods. MPBS, milk (skimmed milk 2%) in PBS.
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and C following the use of Sepharose beads with chem-
ically attached BSA–VprN conjugates and were desig-
nated fragments 1, 2, and 3, respectively (Fig. 2[I] and see
Materials and Methods).
Binding studies revealed that all three purified scFv frag-
ments were able to specifically bind to the BSA–VprN con-
jugate but failed to show any significant binding to the BSA
(nonconjugated) molecules, indicating specific attachment
to the VprN moiety of the conjugate (Fig. 2[II,A]). Binding
was saturable, reaching maximum values at a concentra-
tion of 1 M with fragments 1 and 2 and at 2 M with
fragment 3 (Fig. 2[II,B]). The highest binding specificity and
binding values were exerted by fragment 1, which showed
an about 100-fold higher binding to the BSA–VprN conju-
gate than to conjugates bearing the VprN mutant or the
SV40 NLS (Fig. 2[II,A]). The binding specificities of frag-
ments 2 and 3 were somewhat less pronounced. Both
exhibited, in addition to the high binding values to VprN,
some low, yet detectable binding to the VprN mutant and to
the SV40 NLS (Fig. 2[II,A]).
Binding of the three scFv fragments to their antigen, the
VprN(BSA) molecule, was inhibited by the addition of
soluble BSA–VprN conjugates or free VprN peptides (Fig.
3). However, the BSA–VprN conjugates competed with and
blocked the specific binding of the scFvs much better than
the free VprN peptides (Fig. 3). As can be seen, binding of
fragment 1 to its antigen was inhibited up to 90% in the
presence of about 5MBSA–VprN, while more than 15 M
was needed to exert the same inhibition by the free VprN
peptide. The high inhibitory effect of the BSA–VprN conju-
gate—compared to that of the free VprN peptide—can be
attributed to the fact that each BSA molecule bears about
FIG. 2. [I] SDS–PAGE of the purified anti-VprN scFvs. scFv fragments 1, 2, and 3 (lanes 1–3, respectively) were analyzed using a 12% acrylamide
gel. Please note that fragment 1 is of the lower molecular weight due to the fact that its random CDR3 insert contains only 4 amino acids compared
to the 10 amino acids of fragments 2 and 3. [II] Interaction of the anti-VprN scFv fragments with the BSA–NLS conjugates (A) Binding of fragments
1, 2, and 3 to various BSA–NLS conjugates: , fragment 1; , fragment 2; , fragment 3. (B) The effect of the scFv fragment concentrations on binding
to BSA–VprN: F, fragment 1; , fragment 2; Œ, fragment 3. Binding was estimated using the ELISA system as described under Materials and Methods.
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three or four covalently attached VprN peptides (Friedler et
al., 1999). No or low inhibition was observed by the addition
of a peptide bearing the sequence of the VprNmutant, by its
BSA conjugate, or by the free SV40 NLS peptide or its
conjugate (Fig. 3).
Inhibition of VprN-mediated nuclear import by
anti-VprN scFv fragments
The results in Figs. 4[I] and 4[II] show that the addition
of purified anti-VprN fragments to the in vitro nuclear
FIG. 3. Binding of the anti-VprN scFv fragments to a surface-bound BSA–VprN conjugate: specific inhibition by soluble BSA–VprN conjugate and
VprN peptide. BSA–peptide conjugates and free peptides were mixed with fragments 1–3 at the indicated increasing concentrations. The mixture
obtained was added to surface bound BSA–VprN conjugates. Following incubation for 2 h at 37°C, binding of the scFv fragments to the
surface-attached BSA–VprN was estimated by the ELISA assay system as described under Materials and Methods. F, BSA–VprN conjugate or the
VprN peptide; ‚, BSA–SV40 NLS conjugate or the SV40 NLS peptide; and , BSA–VprN mutant conjugate or the VprN mutant peptide. A, D, fragment
1; B, E, fragment 2; C, F, fragment 3.
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import assay system inhibited VprN-mediated nuclear
import. Inhibition of nuclear import was also observed
when fragment 2 was comicroinjected with BSA–VprN
into intact cultured COS7 cells (Fig. 5). Anti-VprN frag-
ment 2 was selected for most of the experiments in
which inhibition of nuclear import was studied since it
showed the highest binding activity to the recombinant
Vpr–GST and high binding activity to BSA–VprN (see Fig.
6A). However, the inhibitory effects obtained when frag-
ment 1 or 3 was applied (see Fig. 4[II]) were very similar
to those obtained with anti-VprN fragment 2.
The photographs in Fig. 4[I] demonstrate the inhibition
of nuclear import of fluorescently labeled BSA–VprN (FL-
BSA–VprN) conjugates in permeabilized HeLa cells by
fragment 2. The specificity of the scFv fragments can be
inferred from the results showing that no inhibition was
observed when BSA conjugates bearing a different NLS,
such as that of the SV40 NLS, were used as the transport
substrate (Fig. 4[I]B, F). Nuclear import of the BSA–VprN
conjugate was characterized by the same features that
characterize specific and active nuclear import, namely,
like the nuclear import of BSA–SV40 NLS, it was inhibited
by the addition WGA and did not occur at 4°C (Fig. 4[I]C,
D, G and H) (Goldfarb et al., 1986; Karni et al., 1998).
Quantitative estimation of nuclear import using an
ELISA-based assay system (Karni et al., 1998) revealed
that the inhibition observed by the three anti-VprN frag-
ments was between 70 and 90% and close to 0% when
the BSA–VprN and BSA–SV40 NLS conjugates were
used as transport substrates, respectively (Fig. 4[II]).
Similar results were obtained when the effect of the
scFv fragments was studied within the environment of
intact cells. As can be seen in Fig. 5, microinjected
FL-BSA–VprN as well as fluorescently labeled BSA–SV40
NLS (FL-BSA–SV40 NLS) conjugates readily accumu-
lated within the intranuclear space of the microinjected
cells (Figs. 5A and 5B). No nuclear import was observed
when labeled BSA molecules lacking an NLS peptide
were microinjected (Fig. 5E). However, when the same
transport substrates were comicroinjected with fragment
2, complete inhibition of nuclear import was observed in
the cells microinjected with the FL-BSA–VprN (compare
Fig. 5C to Fig. 5D).
The anti-VprN scFv fragments block nuclear import of
the full-length recombinant Vpr–GST fusion protein
The scFv fragments selected by the use of the BSA–
VprN conjugate as a target also recognized a full-length
recombinant Vpr–GST fusion protein. Binding of frag-
ments 2 and 3 to the Vpr–GST fusion protein was very
close to that observed to the BSA–VprN conjugate (Fig.
6A). Fragment 1 showed somewhat lower binding abili-
ties to the recombinant protein compared to the binding
observed with the BSA–VprN conjugate (Fig. 6A). Spec-
ificity of binding can be inferred from the results shown
in Figs. 6B and 6C. Binding of all three scFv fragments to
the Vpr–GST was strongly inhibited by the addition of the
VprN peptide (Fig. 6B) as well as of the BSA–VprN con-
jugate (Fig. 6C). No or marginal inhibition was observed
when the VprN mutant peptide or its BSA conjugate was
added (Figs. 6B and 6C). These results strongly indicate
that the domain with which the scFv fragments interact
within the full-length Vpr protein is the VprN, namely the
domain which includes amino acids 17–34 (Karni et al.,
1998). Figure 6 also shows that to inhibit the binding of
the scFv fragments to the Vpr–GST, much lower concen-
trations of the BSA–VprN conjugate were required com-
pared to those of the VprN peptide. This observation is
consistent with the results obtained by the competition
experiment shown in Fig. 3.
Inhibition of the nuclear import of the fluorescently
labeled recombinant Vpr–GST fusion protein by fragment
2 is demonstrated in Fig. 7. The same results were
obtained using fragments 1 and 3 (not shown). The view
that the nuclear import of the recombinant Vpr–GST pro-
tein is receptor mediated and occurs via the nuclear pore
complex can be inferred from the results showing that it
was inhibited by WGA—the addition of which blocks
active nuclear import (Adam et al., 1990)—and by unla-
beled Vpr–GST fusion protein (Figs. 7C and 7D). Nuclear
import of Vpr–GST was characterized by the same fea-
tures that characterize active nuclear import; namely, it
was ATP dependent, it was partially inhibited by GTP--S,
and its extent was significantly reduced following incu-
bation at 4°C (not shown).
FIG. 4. [I] Inhibition of VprN-mediated nuclear import in permeabilized HeLa cells by anti-VprN scFv fragment 2. Nuclear import was followed by
fluorescence microscopy using FL-BSA–VprN (A) and FL-BSA-SV40–NLS (E) as transport substrates; (B) and (F) as in (A) and (E) but in the presence
of fragment 2 at a molar ratio of scFv:transport substrate of 2:1; (C) and (G) as in (A) and (E) but in the presence of WGA (25 M); (D) and (H) as in
(A) and (E), but nuclear import was performed at 4°C. As can be seen, nuclear import is observed in (A, E, and F) but not in (B–D, G, and H). It should
be noted that although the results in the figure demonstrate specific inhibition at a relatively low scFv:transport substrate ratio (2:1), the specificity
of inhibition was achieved also at higher ratios of at least up to 20:1. [II] Inhibition of VprN-mediated nuclear import by anti-VprN scFv fragments:
quantitative estimation. Nuclear import assay systems contained 1.5 g (20 pmol) of biotinylated BSA–VprN and 0.75 (10 pmol) g of biotinylated
BSA–SV40 NLS conjugates. A volume of 3–4 l containing increasing concentrations of fragment 1, 2, and 3 in PBS was added to the transport
substrates, and the mixture obtained was applied to digitonin-permeabilized Colo-205 cells. Nuclear import of the biotinylated BSA–NLS conjugates
was estimated by the ELISA-based method (Karni et al., 1998; Melchior et al., 1993, and Materials and Methods). Each nuclear import experiment was
repeated at least three times. The data given represent results obtained from one single experiment. Quantitative differences between repeated
experiments never exceeded 20%. White symbols designate biotinylated BSA–SV40 NLS conjugates; black symbols designate biotinylated
BSA–VprN conjugates; F or E, anti-VprN fragment 1; Œ or ‚, anti-VprN fragment 2;  or , anti-VprN fragment 3.
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A synthetic peptide derived from the CDR3 insert of
an anti-VprN scFv fragment binds the BSA–VprN
conjugate but fails to inhibit its nuclear import
It is possible that the binding to the VprN moiety and
the inhibition of nuclear import exerted by the scFv frag-
ments may be promoted, fully or partially, by the random
amino acids inserted into the CDR3 loop of the scFv
domain (Nissim et al., 1994). It was of interest, therefore,
to elucidate the amino acid sequences of this insert and
to study the binding abilities of synthetic peptides carry-
ing these sequences. The corresponding amino acid
sequences encoded by the variable insert in the VH-
CDR3 region of the scFv in the 40 anti-VprN phages
isolated were determined (not shown). However, no con-
sensus sequence could be elucidated between the var-
ious variable insert sequences determined using the
Clastal W (Thompson et al., 1994) and MEME (Bailey and
Elkan, 1994) algorithms.
FIG. 6. Binding of the anti-VprN scFv fragments to the Vpr–GST fusion protein. (A) Binding of the scFv fragments to surface-bound BSA, to VprN–BSA
conjugate, and to the Vpr–GST fusion protein was estimated using the ELISA assay system as described under Materials and Methods. , fragment
1; , fragment 2; ● (gray), fragment 3. (B, C) Binding of the anti-VprN scFv fragments to the full-length Vpr–GST protein: specific inhibition the by
VprN–BSA conjugate and by the VprN peptide. BSA–VprN or BSA–VprN mutant conjugates (B) and VprN or VprN mutant peptides (C) were added to
the scFv fragment solutions at the indicated concentrations. The mixture obtained was added to surface-bound the Vpr–GST protein. Following 2 h
of incubation at 37°C, binding of the scFv fragments to Vpr–GST was estimated by ELISA as described under Materials and Methods. Black symbols
and solid lines: BSA–VprN conjugate or VprN peptide; white symbols and dashed lines: BSA–VprN mutant conjugate or VprN mutant peptide.  or
, fragment 1; F or E, fragment 2; Œ or ‚, fragment 3.
FIG. 5. Inhibition of VprN-mediated nuclear import in microinjected COS7 cells by anti-VprN scFv fragment 2. Cultured COS7 cells were
microinjected (Graessmann and Graessmann, 1983) with 2–3(10)-(11) ml of solutions containing the following: (A) FL-BSA–VprN, (B) FL-BSA–SV40 NLS,
(C) a mixture of FL-BSA–VprN with fragment 2 at a 1:2 molar ratio, (D) FL-BSA–SV40 NLS with fragment 2 at the same ratio as in (C), (E) FL-BSA. Please
note nuclear import in (A, B, and D) but not in (C and E).
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The amino acid sequences of the inserts within scFv
fragments 1–3 are shown in Fig. 8A. Peptides correspond-
ing to these inserts have been synthesized and designated
as peptides a, b, and c, respectively (see Fig. 8A). Of the
three synthetic peptides, only peptide b exhibited specific
binding to the BSA–VprN conjugate, as was determined by
the ELISA assay system (Figs. 8B and 8C). Peptides a and
c, the sequences of which are based on the inserts within
the two other BSA–VprN binders (A and C), failed to bind
this conjugate (Figs. 8B and 8C). Binding of peptide b to the
VprN sequence was saturable and reached maximum val-
ues at a peptide concentration of 1 mM (Fig. 8C). However,
its binding to VprN was only about two- to threefold higher
than that observed with the VprN mutant or the SV40 NLS,
implying that the interaction between peptide b and VprN is
of low affinity (Fig. 8B).
FIG. 7. Inhibition of nuclear import of FL-Vpr–GST by scFv anti-VprN fragment 2. Recombinant Vpr–GST was obtained, fluorescently labeled, and
imported into nuclei of digitonin of permeabilized HeLa cells as described under Materials and Methods. (A) FL-Vpr–GST; (B) FL-Vpr–GST mixed with
fragment 2 in a mole/mole ratio of 1:4; (C) FL-Vpr–GST mixed with WGA (25 M); and (D) FL-Vpr–GST in the presence of fivefold unlabeled Vpr–GST.
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FIG. 8. Interaction of the anti-VprN peptides with the BSA–NLS conjugates. (A) The oligonucleotide sequences of the three random inserts in the
VH–CDR3 loop. (B) Estimation of the binding abilities of the anti-VprN peptides to various BSA–NLS conjugates ( , peptide a; , peptide b; ,
peptide c). (C) Dependency of the binding to the BSA–VprN conjugate on the anti-VprN peptide concentrations (F, peptide a; , peptide b; ‚, peptide c).
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However, even at relatively high concentrations, the
addition of peptide b did not cause any significant re-
duction in the nuclear import of fluorescently labeled
BSA–VprN conjugates into the nuclei of permeabilized
HeLa cells (not shown).
DISCUSSION
The role that the Vpr protein plays in promoting nu-
clear import of the HIV-1 PIC is unclear and controversial
(Heinzinger et al., 1994; Popov et al., 1998; Gallay et al.,
1997; Agostini et al., 2000). The use of the presently
described inhibitory anti-VprN scFvs may offer a new
approach to the study of the requirement of the Vpr
protein for allowing HIV-1 infection in nondividing cells
and for the elucidation of the role of the Vpr protein in
nuclear import of the viral PIC. In addition, inhibition of
nuclear import of viral karyophilic proteins by specific
anti-NLS molecules may lead to the development of a
novel way to combat virus infection in general and the
AIDS disease in particular.
In the present work we have used a phage display
scFv library to obtain specific anti-NLS scFv fragments.
BSA molecules with covalently attached VprN peptide, a
peptide bearing the NLS of the HIV-1 Vpr protein, have
been used as a target for the phage display libraries. The
relatively high percentage of VprN binding phages se-
lected by the use of this conjugate as a target may be
due to the fact that each molecule of the BSA carrier
bears, on average, three to four covalently attached VprN
molecules (Friedler et al., 1999). Furthermore, the phage
particles of the library used possess at the most one
antibody fragment per particle, thus allowing the selec-
tion of antibodies with relatively high affinities (Nissim et
al., 1994; Harrison et al., 1996).
The choice of the VprN peptide as a target was based
on the assumption that it harbors the HIV-1 Vpr NLS,
since this peptide was shown to promote nuclear import
of conjugated BSA molecules as well as of -galactosi-
dase (Karni et al., 1998; Jenkins et al., 1998). This syn-
thetic peptide, which consists of the amino acids 17–34
from the N-terminal domain of the HIV-1 Vpr protein, has
been suggested to possess an -helical structure, prob-
ably similar to that within the intact protein (Luo et al.,
1998; Wecker and Roques, 1999). Bearing a relatively
stable -helical secondary structure makes the VprN
peptide a convenient target for phage display libraries
and for obtaining complementary scFvs or peptides. In-
deed, the three anti-VprN scFv fragments analyzed in this
study possessed high and specific binding activity to the
VprN peptide. The scFvs obtained also interacted with
the full-length recombinant Vpr–GST protein, most likely
recognizing its VprN domain. This can be inferred from
the results showing that the interaction between the scFv
fragments and the recombinant Vpr–GST protein could
be inhibited by the VprN peptide and by its BSA conju-
gate.
It is our view that the most interesting and significant
observation of the present work is the ability of the
anti-VprN scFvs to inhibit nuclear import mediated by the
VprN peptide or of the recombinant Vpr–GST fusion pro-
tein. Quantitative estimation, using an ELISA-based sys-
tem, revealed that the inhibition degree was highly de-
pendent on the mole/mole ratios between the scFv frag-
ments and the VprN. At high molar ratios almost total
inhibition of nuclear import was observed.
The ability of the scFvs to bind to the VprN sequence
as well as to inhibit nuclear import was highly specific.
VprN-mediated but not SV40 NLS-mediated nuclear im-
port was inhibited. Altogether these results strongly in-
dicate that the inhibition observed is due to specific
masking of the VprN moiety by the scFv fragments and
thus prevention of interaction with its putative cellular
receptors. In addition, the inhibition observed within the
microinjected cells suggests that the intracellular envi-
ronment did not promote dissociation of the scFv frag-
ment–VprN complex, indicating a high affinity between
these two proteins.
The inhibition of nuclear import obtained in the
present work by the three anti-VprN scFvs strongly indi-
cates that the VprN domain indeed mediates nuclear
import of the intact Vpr protein. The current view that the
VprN domain is required for the nuclear import is based
mainly on experiments showing that peptides bearing its
sequence promoted nuclear import of nonkaryophilic
proteins (Jenkins et al., 1998; Karni et al., 1998). Our
present results, demonstrating the ability of the anti-VprN
scFvs to totally block nuclear import of the full-length
protein, support the view that the VprN domain is abso-
lutely required for nuclear import of the Vpr protein. It has
also been suggested that the C-terminal domain of the
Vpr bears an NLS sequence that contributes to its karyo-
philic properties (Jenkins et al., 1998). However, in our
previous experiments a synthetic peptide bearing an
amino acid sequence from the C terminus of the Vpr
protein (residues 77–96) failed to mediate nuclear import
of covalently attached BSA molecules (Karni et al., 1998).
Thus, the present results further support our previous
observations indicating that only the N terminus contrib-
utes to the karyophilic properties of this protein. How-
ever, in the present work the Vpr protein was fluores-
cently labeled by covalent attachment of a rhodamine–
maleimide molecule to the cysteine residue located at
the C terminus of this protein (amino acid 76) (Baldrich-
Rubio et al., 2001), as well as to the additional cysteine
residues located in the GST moiety of the Vpr–GST pro-
tein. Therefore, the possibility that the chemical modifi-
cation of the cysteine residue located at the C terminus
(amino acids 73–96) (Jenkins et al., 1998) caused inacti-
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vation of the putative NLS at this domain cannot be
excluded. Moreover, the binding of the relatively high-
molecular-weight anti-VprN scFv (30 kDa) fragment to the
relatively small Vpr protein (11 kDa) may cause masking
of most of the Vpr molecule, including the putative C-
terminal NLS. Also, the GST fusion at the C terminus
itself may mask the putative C-terminal NLS. Thus, our
present results do not completely exclude the possibility
that an additional domain within the Vpr protein, besides
the VprN, may contribute to its karyophilic properties.
Here we have used an isolated peptide, the VprN
peptide, and not the full-length protein as a target for
selecting anti-VprN scFv fragments. This certainly is pref-
erable, especially in cases in which the availability of
highly purified proteins is limited but the domains of
interest and their amino acid sequences within such
proteins are known. Furthermore, by the use of an intact
protein as a target for a phage display library, the gen-
eration of antibodies or peptides complementary to var-
ious epitopes and not necessarily to the desired do-
mains cannot be avoided. Our present results clearly
demonstrate that the scFv fragments selected by the use
of isolated peptide as a target recognized the same
sequence within the intact protein. The drawback of this
approach is that isolated peptides cannot be employed
as a target when the desired epitope is discontinuous
within the intact protein. However, when the detailed 3D
structure of such discontinuous epitopes is known, back-
bone cyclic peptides bearing the corresponding struc-
ture can be designed and synthesized. Such cyclic pep-
tides can then be used as a target for the phage display
library, avoiding again the use of the full-length protein
(Kasher et al., 1999).
Cell-permeable anti-NLS inhibitory peptides may po-
tentially offer an alternative system to that of the scFv
fragments for study of the role of NLS domains in virus
infection. Such inhibitory peptides may also serve as
lead molecules for the development of anti-viral and
anti-HIV drugs. Therefore, attempts were made in the
present work to obtain synthetic peptides the amino acid
compositions of which were based on the sequences of
the CDR3 inserts of the three selected inhibitory scFvs.
However, the peptides obtained either failed to bind the
target VprN peptide or showed low binding affinities
compared to that of the anti-VprN scFvs. The binding
abilities of the anti-VprN peptides may be increased by
error-prone PCR and mutagenesis techniques (Miyazaki
et al., 1999; Saviranta et al., 1998; Harayama, 1998; Ling
and Robinson, 1997) or alternatively by the use of phage
display peptide libraries. Anti-VprN peptides that will
block nuclear import of the viral PIC can serve as lead
compounds for the obtaining of low-molecular-weight
anti-Vpr molecules which potentially can be used for
inhibition of HIV-1 infection.
MATERIALS AND METHODS
Cell cultures
Colo-205 (human colon adenocarcinoma, ATCC CCL
222), COS7, and HeLa cells were maintained in RPMI
1640 (Colo-205 cells) and DMEM (COS7 and HeLa cells)
supplemented with 10% FCS, 0.3 g/L L-glutamine, 100
U/ml penicillin, and 100 U/ml streptomycin (Beit Haemek
Ltd., Kibbutz Beit Haemek, Israel), as previously de-
scribed (Broder et al., 1997).
Synthesis of peptides
The following peptides were synthesized using a pre-
viously described method (Karni et al., 1998): SV40 large
T-antigen NLS (SV40 NLS, 126PKKKRKV132C) (Kalderon et
al., 1984), a peptide bearing the SV40 large T-antigen
NLS in reverse order (“revertant”) (C132VKRKKKPG126), a
peptide derived from the N terminus of the Vpr protein
(VprN,C16NEWTLELLEELKNEAVRHF34) and one from its
C terminus (VprC,C77RHSRIGVTRQRRARNGASRS96),
VprN mutant (C16NEATLELLPELKNPAVRHF34) (Karni et
al., 1998), the HIV-1 Tat-NLS (the ARM sequence,
C48GRKKRRQRRRAHQN61), and a Tat short NLS
(C48GRKKR52) (Friedler et al., 2000). Cysteine residues
were added to the N or to the C terminus of the original
NLS sequences. Peptides derived from the CDR3 ran-
dom insert region of anti-VprN scFv fragments (for se-
quences see Fig. 8C) were synthesized using the same
procedure, and when needed a biotin molecule was
added during the synthesis to the N or C terminus.
Chemical conjugation of the synthetic peptides to
BSA, fluorescently labeled BSA (FL-BSA), and
biotinylated BSA
Conjugation of the synthetic peptides to rhodamine or
biotin-labeled BSA molecules (Sigma Chemical Co. No.
A-7906) was conducted as described before (Adam et al.,
1992; Broder et al., 1997). BSA was labeled with rhoda-
mine (lissamine rhodamine B sulfonyl chloride, mixed
isomers, from Molecular Probes) according to the man-
ufacturer’s instructions and as described before (Karni et
al., 1998). Biotinylated BSA molecules were purchased
from Sigma. The conjugates obtained were concentrated
using a VivaScience concentrator (Sartorius), MWCO
50,000.
Panning and screening of the phage display scFv
library
Panning of the human scFv phage display library (Har-
rison et al., 1996; Nissim et al., 1994) was conducted as
follows: to allow coating with the corresponding protein
molecules, two immunotubes (5 ml, NUNC) were incu-
bated overnight, in parallel, with rotation at room tem-
perature, one with a solution containing the BSA–VprN
conjugate and the other with a solution containing only
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BSA, both at a concentration of 0.1 mg/ml in carbonate
buffer (0.05 M Na2CO3/0.05 M NaHCO3, pH 9.6). Follow-
ing incubation, the tube coated with the BSA–VprN con-
jugates was washed three times with 1 PBS and then
incubated for 2 h at 37°C with 2% (w/v) skim milk (DIFCO)
in 1 PBS (2% MPBS). After an additional three washes
with 1 PBS, the phage library (4 ml in 1% MPBS) was
added and the tube was incubated first for 30 min with
and then for 1.5 h without rotation at room temperature.
The supernatant was removed, and the tube containing
bound phage particles was washed 10 times first with
1 PBS–0.05% Tween 20 and then with 1 PBS. For
elution of surface bound phages, a volume of 1 ml of 0.1
M triethylamine was added and following incubation for
10 min at room temperature with rotation, the triethyl-
amine solution with the eluted phages was collected and
mixed with 0.5 ml of 1 M Tris–HCl, pH 7.4. At the same
time, the tube coated with the BSA molecules was
washed with 1 PBS, incubated with 2% MPBS and
again washed with 1 PBS as described above for the
BSA–VprN-coated tube. The solution containing the
eluted phages was then added to this tube and incu-
bated first for 30 min with, and then for 1.5 h without
rotation at room temperature. The supernatant was col-
lected and used for further screenings using an ELISA
assay system as described below.
PCR for determination of the CDR3 random insert
sequences and of the VH gene segments of the scFv
fragments
The CDR3 random insert sequence and the VH gene
segments of the scFvs were elucidated following PCR of
the scFv domain. DNA from bacteria infected with the
selected phage particles was subjected to several
rounds of amplification with 100 pM oligonucleotide
primers (5CAGGAAACAGCTATGAC3 and 5GAATTTTCT-
GTATGAGG3). The PCR products were purified using the
High Pure PCR Product Purification Kit (from Boehringer
Mannheim) according to the manufacturer’s instructions.
Purity and size (around 900 bp) of the products were
verified by agarose gel electrophoresis. The purified PCR
products were subjected to sequencing.
Expression and purification of soluble anti-VprN scFvs
Expression of soluble scFv fragments in phage-in-
fected bacteria (HB2151) was performed as described
before (Harrison et al., 1996). The expressed anti-VprN
scFvs were purified using CNBr-activated Sepharose (4
Fast Flow from Pharmacia) to which BSA–VprN conju-
gates were covalently linked according to the manufac-
turer’s instructions. A volume of 8–10 ml of the expressed
scFv fragment preparations was mixed with 2 ml of the
BSA–VprN–Sepharose beads and incubated with rota-
tion for 1 h at 4°C. At the end of the incubation period the
beads were washed with 10 ml of the following solutions:
first with PBS, second with PBS–0.5 M NaCl, third with
0.2 M Glycine, pH 6, and finally with 0.2 M Glycine, pH 5.
The bound scFv fragments were eluted by incubation of
the washed Sepharose beads with 5 ml of 0.2 M Glycine,
pH 3, for 20–30 min at 4°C with rotation. Following 5 min
of centrifugation at 1000 rpm, the supernatant obtained
was immediately mixed with 1 M Tris–HCl, pH 7.4, dia-
lyzed against 0.1 PBS, and then concentrated 10
using the SpeedVac Concentrator. The purity of the scFv
fragments was analyzed by SDS–PAGE (Laemmli, 1970)
with Mini-PROTEAN 3 Cell (from Bio-Rad) using a 12%
acrylamide gel (see Fig. 2[I]).
Determination of ligand–NLS binding by the ELISA
assay system
The various ELISA assays used in the present work
were—in general—carried out as follows (for further
details see the legends to the figures): MaxiSorb plates
(NUNC) were incubated overnight at 4°C with 200 l of
a solution containing 25–100 g/ml of the corresponding
antigen (usually an NLS–BSA conjugate) in carbonate
buffer (0.05 M Na2CO3/0.05 M NaHCO3, pH 9.6). Follow-
ing removal of the antigen solution, the plates were
washed three times with 1 PBS and were then blocked
with 200 l of 2% BSA in 1 PBS (for scFv fragments) or
2% skim milk (DIFCO) in 1 PBS (for the peptides and
phages) for 2 h at 37°C. Following three washes with 1
PBS, the appropriate ligand in a total volume of 200 l of
a blocking solution was added and the plates were
incubated for another 2 h at 37°C (100 l of phage
supernatant mixed with 100 l 2% MPBS, 25 g/ml of
scFv fragment solution in 2% BSA in 1 PBS, or 100
g/ml of peptide solution in 2% MPBS, if not specified
otherwise). The plates were rewashed three times with
1 PBS, and a volume of 200 l of the following re-
agents—all dissolved in the appropriate blocking solu-
tions—was added for detection of the antigen–ligand
complexes: Avidin-POD (Roshe Diagnostics) for biotin-
labeled molecules (1 U/ml), anti-M13 monoclonal anti-
body (Amersham Pharmacia, 1:5000), for the bound
phages, and a mix of mouse anti-myc antibody (Sigma,
1:1000) with anti-mouse–HRP antibody (Sigma, 1:2000)
for the scFv fragments. Following incubation for 1 h at
37°C, the plates were washed three times with 1 PBS
and the appropriate substrate was added according to
the manufacturer’s instructions. Each of the binding ex-
periments was repeated at least three times. However,
the data given in the figures represent results obtained
from one single experiment. Quantitative differences be-
tween repeated experiments never exceeded 15%.
Quantitative estimation of nuclear import
Nuclear import was quantitatively determined by the
ELISA-based method using biotinylated BSA–NLS trans-
port substrates as described before (Melchior et al.,
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1993) and in Friedler et al. (1998), with the below-de-
scribed modifications. The Colo-205 cells were perme-
abilized using 1 ml of 40 g/ml digitonin (Fluka) per 107
Colo-205 cells as follows: half of the volume of the
digitonin solution was applied and the remaining volume
was added gradually in portions of 100–200 l. After
each addition a sample of cells was examined by phase
microscopy, and when 70–80% of the cells appeared
permeabilized, the process was terminated by 50- to
100-fold dilution with cold transport buffer (Melchior et
al., 1993).
Expression and purification of the Vpr–GST fusion
protein
A bacteria culture (strain AN3347) carrying a plasmid
bearing the Vpr–GST fusion protein (Piller et al., 1996)
was grown with 2 TY medium supplied with 100 g/ml
of ampicilin at 37°C with shaking (225 rpm) until it
reached an optical density of 0.9 at 600 nm. Protein
expression was induced by 0.1 mM IPTG, and the culture
was grown overnight (about 16 h) at 28°C with shaking
as above. Following centrifugation (12,000 g, 15 min,
Sorvall), the pellet obtained was suspended in 10 mM
Tris–HCl buffer (1/100–1/50 of the original volume of the
culture) and subjected to six 1-min cycles of sonication.
The turbid solution obtained was centrifuged as above,
and the supernatant obtained was added to preswelled
glutathione–agarose resin (Sigma, No. G4510) in a vol/vol
ratio of about 1 ml resin/20 ml solution and incubated
with rotation overnight at 4°C. The agarose resin was
then intensively washed in batches with 1 PBS (50–100
ml of 1 PBS per 1 ml resin), and the bound Vpr–GST
was eluted by incubation of the washed resin with 1
PBS containing 30 mM of free Glutathione and 3 mM of
DTT with rotation at 4°C for 1 h. The eluted protein was
concentrated by VivaScience concentrators, MWCO
30,000 (Sartorius) and stored at 20°C.
Fluorescent labeling of the recombinant Vpr–GST
protein
The Vpr–GST fusion protein which was eluted from the
glutathione–agarose resin was concentrated by Viva-
Science concentrators (MWCO 30,000) to give a final
concentration of 2.5–3.0 mg/ml, dialyzed for 2–3 h
against 1 PBS at 4°C, and labeled with rhodamine–
maleimide (Molecular Probes) according to the manufac-
turer’s instructions. Following 2 h of incubation at room
temperature with rotation, the labeled Vpr–GST fusion
protein (FL-Vpr–GST) was purified using Sephadex G-25
fine (Pharmacia). The FL-Vpr–GST was concentrated
again using VivaScience concentrators (MWCO 30,000)
and stored at 20°C.
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